Nothofagin

Research use only, not for human use.

Nothofagin has antioxidant, and antithrombotic activities, it possesses anti-inflammatory activity by inhibiting hyperpermeability, expression of CAMs, and adhesion and migration of leukocytes, thereby endorsing its usefulness as a therapy for vascular inflammatory diseases.

Nothofagin, a dihydrochalcone, is isolated from rooibos (Aspalathus linearis). Nothofagin downregulates NF-κB translocation through blocking calcium influx. Nothofagin has antioxidant activity and ameliorates various inflammatory responses such as the septic response and vascular inflammation.

Nothofagin pre-treatment (0.1, 1, 10 μM) decreases the level of histamine release in RBL-2H3 and RPMCs cells. The production of cytokines are downregulated bynothofagin pre-treatment Nothofagin (TNF-α: 1-10 μM; IL-4: 0.1-10 μM, IL-6: 1-10 μM).Pre-treatment of DNPHSA-stimulated RBL-2H3 with Nothofagin (10 μM) markedly suppresses the phosphorylation of Lyn, Syk, and Akt.Nothofagin (30 μM; for 6 hours) results in inhibited formation of LPS-induced (100 ng/mL; 4 hours) paracellular gaps with the formation of dense F-actin rings in HUVECs. Nothofagin suppresses IgE-mediated mast cell degranulation both in vitro and in vivo.

Nothofagin (1 mg/kg; orally; once a day; for 7 days) significantly increases the urinary volume of both normotensive (NTR) and spontaneously hypertensive rats (SHR).Animal Model:Male Wistar normotensive and spontaneously hypertensive rats (3-4 months old) Dosage:1 mg/kg Administration:Orally; once a day; for 7 days Result:Significantly increased the urinary volume of both NTR and SHR.

——

Apoptosis

IL Receptor

IL Receptor | ERK | TNF

——

——

11023-94-2

436.41

C21H24O10

>98% (HPLC)

——

OC1=C(C(O)=CC(O)=C1C(CCC2=CC=C(O)C=C2)=O)[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O

——

(-20℃)

With Ice Pack

≥ 2 years